Cryopreservation and Enumeration of Human Endothelial Progenitor and Endothelial Cells for Clinical Trials

Bogoslovsky, Tanya; Wang, D; Maric, Dragan; Scattergood-Keepper, Lindsay; Spatz, Maria; S, Auh; Hallenbeck, John M.

doi:10.4172/2155-9864.1000158

Cited by 7 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many factors such as composition of cells, cell type, cell density freezing and thawing rate, can affect the EPCs cryopreservation efficacy (36,37). Thawing and freezing can result in a decrease in EPC marker expression, proliferation, differentiation and artery injury recovery which may affect EPCs functions and viability (38,39). EPC have been stored by freezing peripheral blood, bone marrow and UCB derived MNCs.…”

Section: Epc Storagementioning

confidence: 99%

Endothelial Progenitor Cells: A Brief Update

Tariq,

Lee,

Kim

2023

Int J Stem Cells

View full text Add to dashboard Cite

An enormous amount of current data has suggested involvement of endothelial progenitor cells (EPCs) in neovasculogenesis in both human and animal models. EPC level is an indicator of possible cardiovascular risk such as Alzheimer disease. EPC therapeutics requires its identification, isolation, differentiation and thus expansion. We approach here the peculiar techniques through current and previous reports available to find the most plausible and fast way of their expansion to be used in therapeutics. We discuss here the techniques for EPCs isolation from different resources like bone marrow and peripheral blood circulation. EPCs have been isolated by methods which used fibronectin plating and addition of various growth factors to culture media. Particularly, the investigations which tried to enhance EPC differentiation while inducing with growth factors and endothelial nitric oxide synthase are shared. We also include the cryopreservation and other storage methods of EPCs for a longer time. Sufficient amount of EPCs are required in transplantation and other therapeutics which signifies their in vitro expansion. We highlight the role of EPCs in transplantation which improved neurogenesis in animal models of ischemic stroke and human with acute cerebral infarct in the brain. Accumulatively, these data suggest the exhilarating route for enhancing EPC number to make their use in the clinic. Finally, we identify the expression of specific biomarkers in EPCs under the influence of growth factors. This review provides a brief overview of factors involved in EPC expansion and transplantation and raises interesting questions at every stage with constructive suggestions.

show abstract

Section: Epc Storagementioning

confidence: 99%

Endothelial Progenitor Cells: A Brief Update

Tariq,

Lee,

Kim

2023

Int J Stem Cells

View full text Add to dashboard Cite

show abstract

“…A peripheral blood mononuclear cell (PBMNC) is any peripheral blood cell having a round nucleus, consisting of lymphocytes (T cells, B cells, NK cells) and monocytes ( 49 ). The EPCs could also be identified in isolated PBMNC, although only as a small fraction ( 50 ). As the mononuclear cells in the peripheral blood originally come from bone marrow, these cells could be stimulated or mobilized by giving a systemic injection of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase the number in the peripheral blood without affecting its function and capacity ( 51 - 53 ).…”

Section: Peripheral Blood Mononuclear Cells (Pbmnc)mentioning

confidence: 99%

Autologous Bone-Marrow vs. Peripheral Blood Mononuclear Cells Therapy for Peripheral Artery Disease in Diabetic Patients

Yunir

Kurniawan

Rezaprasga

et al. 2021

IJSC

View full text Add to dashboard Cite

Diabetes mellitus (DM) remains one of the most important risk factors for peripheral artery disease (PAD), with approximately 20% of DM patients older than 40 years old are affected with PAD. The current standard management for severe PAD is endovascular intervention with or without surgical bypass. Unfortunately, up to 40% of patients are unable to undergo these revascularization therapies due to excessive surgical risk or adverse vascular side effects. Stem cell therapy has emerged as a novel therapeutic strategy for these ‘no-option’ patients. Several types of stem cells are utilized for PAD therapy, including bone marrow mononuclear cells (BMMNC) and peripheral blood mononuclear cells (PBMNC). Many studies have reported the safety of BMMNC and PBMNC, as well as its efficacy in reducing ischemic pain, ulcer size, pain-free walking distance, ankle-brachial index (ABI), and transcutaneous oxygen pressure (TcPO2). However, the capacity to establish the efficacy of reducing major amputation rates, amputation free survival, and all-cause mortality is limited, as shown by several randomized placebo-controlled trials. The present literature review will focus on comparing safety and efficacy between BMMNC and PBMNC as cell-based management in diabetic patients with PAD who are not suitable for revascularization therapy.

show abstract

Bone marrow derived endothelial progenitor cells retain their phenotype and functions after a limited number of culture passages and cryopreservation

Gong

Yang

et al. 2018

Cytotechnology

View full text Add to dashboard Cite

A critical limitation for tissue engineering and autologous therapeutic applications of bone marrow derived EPCs is their low frequency, which is even lower in number and activity level in patients with cardiovascular risk factors and other diseases. New strategies for obtaining and reserving sufficient ready-to-use EPCs for clinical use have hit major obstacles, because effects of serial passage and cryopreservation on EPC phenotype and functions are still needed to be explored. The present study aims at investigating effects of a limited number of culture passages as well as cryopreservation on EPC phenotype and functions. We isolated EPCs from rat bone marrow and cultured them up to passage 12 (totaling achievements of 40 population doublings). The phenotype and functions of fresh cultured and postcryopreserved EPCs at passages 7 and 12, respectively, were evaluated. EPCs at passage 12 maintained the morphological characteristics, marker phenotype, Dil-ac-LDL uptake and FITC-UEA-1 binding functions, enhanced EPCs proliferation, tube formation and migration, but decreased CD133 expression compared with EPCs at passage 7. Cryopreservation caused limited impairment in EPC phenotype and functions. In brief, our results demonstrated that a limited number of culture passages and cryopreservation did not change EPC phenotype and functions, and can be used for the development of robust strategies and quality control criterion for obtaining sufficient and high-quality ready-to-use EPCs for tissue engineering and therapeutic applications.

show abstract

Cryopreservation and Enumeration of Human Endothelial Progenitor and Endothelial Cells for Clinical Trials

Cited by 7 publications

References 46 publications

Endothelial Progenitor Cells: A Brief Update

Endothelial Progenitor Cells: A Brief Update

Autologous Bone-Marrow vs. Peripheral Blood Mononuclear Cells Therapy for Peripheral Artery Disease in Diabetic Patients

Bone marrow derived endothelial progenitor cells retain their phenotype and functions after a limited number of culture passages and cryopreservation

Contact Info

Product

Resources

About